Antidepressant-induced Burning Mouth Syndrome
- A Unique Case

Department of Oral Medicine and Radiology, KLE Society’s Institute of Dental Sciences,
*Vokkaliga Sangha Dental College and Hospital, Bangalore, India

Shubhasini Attavar Raghavan, Rajiv Nidasale Puttaswamiah*, Praveen N Birur,
Bhanushree Ramaswamy, and Sumsum P Sunny

Burning Mouth Syndrome (BMS) is defined as a chronic orofacial pain syndrome, without evidence of mucosal lesions and other clinical signs of disease or laboratory abnormalities. Patients with BMS complain of burning pain in the mouth, xerostomia and taste disturbances. It is more common among women and the median age of occurrence is about 60 years. BMS may be primary or secondary to other diseases. The mainstay in the treatment of BMS includes antidepressants, benzodiazepines, and anticonvulsants. A few cases of BMS caused due to medication have been reported. The causative drugs include angiotensin-converting enzyme inhibitors, anticoagulants, antipsychotics, antiretrovirals, and benzodiazepines. This is a case report of a patient on antidepressants who developed symptoms of BMS thereby causing a dilemma in management. (Korean J Pain 2014; 27: 294-296)

Key Words:
antidepressants, burning mouth syndrome, drug-induced BMS, fluoxetine, SSRI.

CASE REPORT

A 55-year-old female patient presented with a four-month history of a continuous burning sensation of the oral mucosa. It was initially present only on the tongue but gradually involved the entire mouth. The burning sensation was not associated with an altered taste sensation or dry mouth. It developed in the morning and progressively increased in intensity throughout the day. It was aggravated by spicy food and not relieved when taking analgesics.

Her medical history revealed that the patient had been...
Burning mouth syndrome is defined by the International Association for the Study of Pain as burning pain in the tongue or other oral mucous membrane associated with normal signs and laboratory findings, lasting for at least 4 to 6 months [3]. One of the most commonly affected sites is the tip and anterior two thirds of the tongue, which are the areas of greatest movement in the oral cavity [4]. The prevalence of burning mouth symptoms reported by international studies ranges from 0.6% to 15% [5]. Patients are around 60 years of age, and females are more commonly affected than males [6].

Lamey and Lewis [7] have suggested classifying BMS into three patterns: types 1, 2, and 3. Type 1 includes symptom–free waking, with sensations developing in the morning and progressively rising to a severe level by evening. Type 2 involves continuous symptoms throughout the day; whereas type 3 features intermittent symptom–free periods throughout the day. Nonpsychologic causative factors, such as nutritional deficiencies, have been linked to type 1, chronic anxiety to type 2, and food allergies to type 3.

Another approach in classifying BMS is to divide patients into either primary or secondary groups. While primary BMS is idiopathic, secondary BMS may be caused by local factors or systemic conditions. Local factors associated with BMS include mucosal diseases, fungal infections, bacterial invasion, allergies, temporomandibular joint dysfunctions, and salivary gland abnormalities. Deficiency diseases, hormonal and immunologic disturbances, and pharmacotherapeutic side effects are included in the systemic conditions [8].

Secondary BMS requires appropriate diagnosis and treatment of the underlying condition to manage symptoms. In primary BMS, the cause is unclear and counselling and medication remain the mainstay of treatment [9].

Patton et al. [10] set out the guidelines for the management of primary BMS based on a systematic review of randomized controlled trials, and recommended the following drugs: SSRI, clonazepam, alphalipolic acid, amisulpride and cognitive behavioral therapy.

However, several medications have been reported to induce BMS. These include the following: efavirenz, clonazepam, hormonal replacement therapies, fluoxetine, sertraline and a broad range of antihypertensive agents such as captopril, endapril, and lisinopril [11]. Thirty–three percent of drug–induced BMS have been seen to be dose–dependent phenomena, because the burning sensation appears after elevating the drug dose in search of increased therapeutic efficacy [12].

Levenson [13] reported a case of a patient with major depression who developed BMS after an increase in the dosage of SSRI (fluoxetine, sertraline) and whose burning...
sensation was completely relieved after discontinuation of the medication.

The pathogenesis of BMS has been described in terms of local factors or conditions that alter the peripheral nerves, resulting in a decreased threshold of burning sensation and peripheral sensitization. If the peripheral sensitization continues for a long period of time, it adversely affects the central nervous system and results in neuroplasticity and central sensitization [14]. Antidepressants decrease the delay in neurotransmission by increasing neurotransmitters in the synapses, SSRIs block the reabsorption of serotonin by nerve cells in the brain. This leaves more serotonin available, which enhances neurotransmission. This improves the depressive state of the patient [15].

However, serotonin has a central analgesic effect but acts as an algogenic peripherally. Our patient was on SSRIs for the management of depression. The dose of her medication was increased to improve the efficacy of treatment for her depression. However, this resulted in the symptoms of a burning mouth. This probably occurred because of the peripheral algogenic action of serotonin.

This is a case report of a patient who developed BMS while on antidepressants. The purpose of this article is to bring to light this rare occurrence. Cessation of the drug is the best way to manage such patients after obtaining physician consultation for the medical management of depression.

REFERENCES

1. Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome. Am Fam Physician 2002; 65: 615–20.
2. Scala A, Checchi L, Montevcchi M, Marini I, Giamberardino MA. Update on burning mouth syndrome: overview and patient management. Crit Rev Oral Biol Med 2003; 14: 275–91.
3. Merskey H, Bogduk N: Task Force on Taxonomy of the International Association for the Study of Pain. Lesions of the ear, nose, and oral cavity, In: Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms, 2nd ed. Seattle (WA): IASP Press; 1994, pp 74–5.
4. Grushka M. Clinical features of burning mouth syndrome. Oral Surg Oral Med Oral Pathol 1987; 63: 30–6.
5. Zakrzewska JM, Hamlyn PJ. Facial pain, In: Epidemiology of pain: a report of the Task Force on Epidemiology of the International Association for the Study of Pain, Edited by Crombie IK, Croll PR, Linton SJ, LeResche L, Von Korff M. Seattle (WA): IASP Press; 1999, pp 175–82.
6. Lamey PJ. Burning mouth syndrome: approach to successful management. Dent Update 1998; 25: 298–300.
7. Lamey P, Lewis MA. Oral medicine in practice: burning mouth syndrome. Br Dent J 1989; 167: 197–200.
8. Cibrka RM, Nelson SK, Leolbvre CA. Burning mouth syndrome: a review of etiologies. J Prosthet Dent 1997; 78: 93–7.
9. Klasser GD, Fischer DJ, Epstein JB. Burning mouth syndrome: recognition, understanding, and management. Oral Maxillofac Surg Clin North Am 2008; 20: 255–71, vi.
10. Paton LL, Siegel MA, Benoile R, De Laat A. Management of burning mouth syndrome: systematic review and management recommendations, Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103 Suppl: S39. e1–13.
11. Lauria G, Majorana A, Bograna M, Lombardi R, Penza P, Padovani A, et al. Trigeminal small-fiber sensory neuropathy causes burning mouth syndrome. Pain 2005; 115: 332–7.
12. Salort-Llorca C, Minguez-Serra MP, Silvestre FJ. Drug-induced burning mouth syndrome: a new etiological diagnosis. Med Oral Patol Oral Cir Bucal 2008; 13: E167–70.
13. Levenson JL. Burning mouth syndrome as a side effect of SSRIs. J Clin Psychiatry 2003; 64: 336–7.
14. Okeson JP. The various presentations of pain, In: Bell’s orofacial pains: the clinical management of orofacial pain, 6th ed. Chicago (CA): Quintessence, 2005, pp 107–28.
15. Rang HP, Dale MM, Ritter J, Flower RJ, Henderson G. Antidepressant drugs, In: Rang and Dale’s pharmacology. 7th ed. Edinburgh: Elsevier/Churchill Livingstone; 2012, pp 564–83.